Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease

Inflammatory Bowel Diseases

Volumn 18, Issue 4, 2012, Pages 750-757

  Jung, Yoon Suk ^a   Cheon, Jae Hee ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Azathioprine; Intestinal Behcet's disease; Relapse; Remission; Thiopurine

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; HEMOGLOBIN; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BEHCET DISEASE; CORTICOSTEROID THERAPY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROPATHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUTH ULCER; NAUSEA AND VOMITING; PARENTERAL NUTRITION; PATIENT CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGE OF ONSET; AZATHIOPRINE; BEHCET SYNDROME; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858704854     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21757     Document Type: Article

References (40)

1. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol. 2007;42:737-745. (Pubitemid 47456761)
2. Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Engl J Med. 1999;341:1284-1291. (Pubitemid 29489745)
3. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492-2499.
4. Cheon JH, Celik AF, Kim WH. Behçet's disease: gastrointestinal involvement. In: Yazici Y, Yazici H, eds. Behçet's Syndrome. New York: Springer; 2010:165-188.
5. Shimizu T, Ehrlich GE, Inaba G, et al. Behcet disease (Behcet syndrome). Semin Arthritis Rheum. 1979;8:223-260. (Pubitemid 9200080)
6. Chang HK, Kim JW. The clinical features of Behcet's disease in Yongdong districts: analysis of a cohort followed from 1997 to 2001. J Korean Med Sci. 2002;17:784-789.
7. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol. 2000;30:144-154. (Pubitemid 30148442)
8. Ebert EC. Gastrointestinal manifestations of Behcet's disease. Dig Dis Sci. 2009;54:201-207.
9. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66:517-528.
10. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000: CD000067.
11. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009;104: 2089-2096.
12. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. J Clin Gastroenterol. 2010;44:e116-122.
13. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum. 2000;43:692-700. (Pubitemid 30324610)
14. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis. 2011;17:605-613.
15. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530. (Pubitemid 34117002)
16. Thia KT, Li M, Ling KL, et al. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809-815.
17. Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588.
18. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978;2:955-957. (Pubitemid 9061740)
19. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219. (Pubitemid 26035245)
20. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol. 1999; 94:3254-3257.
21. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37: 674-678.
22. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2010 [Epub ahead of print].
23. Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1995;37:811-818.
24. Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-586. (Pubitemid 26293220)
25. Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40:1211-1215.
26. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157:901-906. (Pubitemid 47583484)
27. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812-1818. (Pubitemid 40824692)
28. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80-85.
29. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15:1485-1491.
30. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
31. Steinhardt HJ, Loeschke K, Kasper H, et al. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion. 1985;31:97-108. (Pubitemid 15100650)
32. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594.
33. Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010;44:e242-248.
34. Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn's disease. Intest Res. 2009;7:22-31.
35. Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol. 2009;44:197-203.
36. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13:563-567. (Pubitemid 39214035)
37. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006;101:2769-2776. (Pubitemid 44902649)
38. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44-49. (Pubitemid 43129523)
39. Cheon JH, Kim JH, Kim BY, et al. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. Hepatogastroenterology. 2009;56:421-423.
40. Jung YS, Cheon JH, Park JJ, et al. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. J Hum Genet. 2010;55:121-123.